Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing.
CD38
CD47
Immunohematology
Monoclonal antibody therapy
Pretransfusion testing
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
entrez:
31
8
2019
pubmed:
31
8
2019
medline:
26
5
2020
Statut:
ppublish
Résumé
Novel monoclonal antibody therapies are increasing in number and clinical significance as their role in oncologic formularies expands. Anti-CD38 and anti-CD47/SIRPα agents commonly interfere with pretransfusion compatibility testing. Anti-CD38 interference is mitigated by dithiothreitol, which disrupts CD38 antigen on reagent red cells; however, this modification limits rule-out of all clinically significant antibodies. Several anti-CD47 agents are in clinical trials and demonstrate wide variability in pretransfusion testing interference. Modifications to pretransfusion testing can limit interference by anti-CD47 agents. Rapid dissemination of knowledge of these monoclonal antibody agents to the broader transfusion medicine community is paramount for continued patient transfusion safety.
Identifiants
pubmed: 31466605
pii: S0889-8588(19)30065-6
doi: 10.1016/j.hoc.2019.05.007
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
CD47 Antigen
0
CD47 protein, human
0
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
797-811Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.